Ipsen - Novembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de...
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights...
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Ipsen secures exclusive global rights to develop, manufacture and...
Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potentialBMX-502 is a bispecific antibody...
Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe thérapeutique en immuno-oncologie Ipsen obtient les droits mondiaux...
Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG Ipsen met en avant...
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS Ipsen presents 3 late-breaking presentations and 8 abstracts across...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today...
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus Ipsen presents 3 late-breaking presentations and 8 abstracts...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.8 | 0.744186046512 | 107.5 | 111.3 | 105.6 | 66915 | 109.27327937 | DE |
4 | -1.7 | -1.54545454545 | 110 | 113.3 | 105.5 | 65437 | 109.47336357 | DE |
12 | -3.2 | -2.86995515695 | 111.5 | 117.5 | 105.5 | 60509 | 111.29820916 | DE |
26 | -17.2 | -13.7051792829 | 125.5 | 126 | 100.3 | 66406 | 110.57509248 | DE |
52 | 6.6 | 6.48967551622 | 101.7 | 126.7 | 99.7 | 70235 | 110.10472021 | DE |
156 | 16.54 | 18.0252833479 | 91.76 | 130.7 | 77 | 80174 | 104.56092682 | DE |
260 | 28.05 | 34.953271028 | 80.25 | 130.7 | 34.2 | 101337 | 88.95900026 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales